Results for tag: "Hypomethylating Agent"

The Hypomethylating Agent market within the context of Oncology Drugs is a rapidly growing sector of the pharmaceutical industry. Hypomethylating agents are drugs used to treat certain types of cancer, such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These drugs work by inhibiting the activity of enzymes that add methyl groups to DNA, which can lead to the development of cancer. Hypomethylating agents are used in combination with other treatments, such as chemotherapy and radiation therapy, to improve patient outcomes. The market for hypomethylating agents is expected to continue to grow as more patients are diagnosed with cancer and as new treatments become available. Additionally, the development of new drugs and the increasing availability of generic versions of existing drugs are expected to drive market growth. Some of the major companies in the Hypomethylating Agent market include Celgene Corporation, Novartis AG, Pfizer Inc., Merck & Co., Inc., and Bristol-Myers Squibb Company. Show Less Read more